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1. Introduction 
 
 
Cardiovascular diseases, and in particular, cardiac arrhythmias, such as ventricular 
fibrillation have a leading role in mortality in developed countries. The most serious 
ventricular arrhythmia – ventricular fibrillation – causes the death of more than 3.000.000 
people all over the world and 300.000 – 350.000 people in the USA and Europe annually, 
which statistically means that one person dies every minute on each continent. In Hungary 
exact data are not available, but according to calculations there are 25.000 – 26.000 sudden 
cardiac death cases annually, or 50 – 60 deaths per day. In the majority of the cases sudden 
cardiac death occurs when victims are not in hospital, consequently, survival probability is 
very low. Most frequently (50 %) the background of the on-the-spot diagnosed circulation 
collapse is ventricular tachycardia /fibrillation/. Sudden cardiac death is often the very first 
sign of the symptom-free cardiovascular disease. Sudden cardiac death is a complex national 
health problem affecting families and having significant social and economic consequences, 
since usually it is the head of the family, a seemingly healthy man, who dies tragically. 
Survivors of the crisis can live a life of full volume in good conditions provided that they get 
the most appropriate treatment. Accordingly, cardiac arrhythmias represent a major area of 
cardiovascular research. One of the main goals of pharmacological research is to develop a 
safe ventricular antiarrhythmic drug that can be applied either in acute cases or for treating 
postinfarction patients.  
According to the classification of Vaughan Williams (1970), based on 
electrophysiological actions, the antiarrhythmic drugs can be defined by four classes. Class I 
consist of antiarrhythmic agents that block sodium channels, reducing the maximum increase 
rate of depolarization (Vmax ). Class II agents are the β-blockers, the Class III drugs act 
through delaying repolarization of cardiac myocytes and thus cause a lengthening of APD 
(potassium-channel blockers), while Class IV antiarrhythmics block calcium currents in 
cardiac tissue. 
Concepts regarding the treatment of cardiac arrhythmias changed significantly in the 
past decade, owing to the revolutionary development of electrophysiological methods (patch-
clamp, molecular biology). The Cardiac Arrhythmia Suppression Trial (CAST) showed that 
flecainide and encainide, two Class I/C sodium channel blocker antiarrhythmic drugs, 
increased mortality rates approximately threefold compared with placebo due to 
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proarrhythmic effects. Consequently, the interest of drug development for treatment of 
ventricular tachycardia (VT) and atrial fibrillation (AF) has been shifted toward those agents 
that prevent and terminate re-entrant arrhythmias by prolonging the action potential duration 
(APD) and effective refractory period (ERP), resulting in an increase in arrhythmia 
wavelength and a block development within the re-entrant circuit. 
Class III antiarrhythmic action, i.e. lengthening of cardiac action potential duration 
(APD) and prolongation of the repolarization, is usually caused by blockade of one or more 
potassium channels. Sodium channels are not affected, thus conduction velocity remains 
unchanged. A great number of non-cardiac drugs cause lengthening of repolarization in both 
ventricular muscle cells and Purkinje fibres by using a similar mode of action. 
One arrhythmogen factor that can result in ventricular arrhythmias occurring in 
myocardial ischaemia or poisoning with digitalis is delayed afterdepolarization (DAD), which 
arises in heart muscle cells following Ca2+ overload. Reducing the incidence of these trigger 
mechanism (DAD) or their pharmacological blockade would be extremely desirable from a 
clinical point of view. 
 Maintenance of the Ca2+ homeostasis in the myocardium is mainly regulated by the 
sodium-calcium exchanger (NCX). Mammalian Na+/Ca2+ exchangers are members of three 
branches of a much larger family of transport proteins [the CaCA (Ca2+/cation antiporter) 
superfamily] whose main role is to provide control of Ca2+ flux across the plasma membranes 
or intracellular compartments. Since cytosolic levels of Ca2+ are much lower than those found 
extracellularly or in sequestered stores, the major function of NCX is to extrude Ca2+ from the 
cytoplasm. The exchangers are, however, fully reversible and thus, under special conditions 
of subcellular localization and compartmentalized ion gradients, NCX may allow Ca2+ entry 
and may play more specialized roles in Ca2+ movement between compartments. The NCX 
branch of Na+/Ca2+ exchangers comprises three members: NCX1 has been most extensively 
studied, and is broadly expressed with particular abundance in heart, brain and kidney, NCX2 
is expressed in brain, and NCX3 is expressed in brain and skeletal muscle.  
It is known that NCX, at the forward mode, extrudes Ca2+ from the cell to the 
extracellular space during diastole, at relatively low free cytoplasmic Ca2+ concentration and 
negative transmembrane potential. Since the extrusion of one Ca2+ is coupled with 3 Na+ 
entering the cell, during the forward mode of the NCX net inward current is carried, which 
can cause substantial depolarization leading to early (EAD) and delayed (DAD) after-
depolarizations, especially when intracellular Ca2+ is elevated. EAD and DAD is generally 
thought to play an important role in arrhythmogenesis, especially in conditions where 
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potassium conductance is decreased, such as heart failure. Therefore one may speculate that 
specific blockers of NCX could be potential antiarrhythmics in dysrhythmias related to Ca2+ 
overload. This hypothesis could not be directly tested since the available NCX inhibitors, at 
least in higher concentrations, also decreased the L-type calcium current (ICa) which in turn 
decreased intracellular Ca2+ load, thereby indirectly changing the magnitude of NCX. In 1996 
it was found that KB-R7943 (2-[2-[4-94-nitrobenzyloxy)phenyl]ethyl]isothiourea), an 
effective inhibitor of NCX in the reverse mode but not in the forward mode, reduced the 
incidence of ischaemia and reperfusion arrhythmia induced by calcium overload. However, 
KB-R7943 also inhibits the L-type calcium current which makes the interpretation of its 
antiarrhythmic effect rather uncertain.  
In 2001, Matsuda et al. reported SEA-0400 (2-[4-[(2,5-difluorophenyl)methoxy]phe-
noxy]-5-ethoxy-aniline), a newly developed, more potent, and selective NCX inhibitor. It is 
completely coincidental that SEA-0400 and KB-R7943 have a common benzyloxyphenyl 
structure, suggesting that this portion is important for inhibitory action against NCX.  
SEA-0400 is highly specific for NCX because it hardly inhibits other receptors, channels and 
transporters. In 2002, SN-6 was found by screening newly synthesized benzyloxyphenyl 
derivatives for NCX1 inhibition. This compound showed inhibitory potency for NCX1 similar 
to KB-R7943, but was more specific for NCX1 than KB-R7943. 
One of the goals of my PhD project was to investigate the effect of SEA-0400 on the 
NCX and ICa currents of dog ventricular myocytes, and also on the formation of EAD and 
DAD in the dog ventricular muscle and Purkinje fibres, using the conventional microelectrode 
and patch-clamp techniques. 
In the case of antiarrhythmic drugs the delicate balance between drug efficacy and 
unexpected adverse side effects is narrower than in any other class of therapeutic agents. 
Sotalol, amiodarone, ibutilide and dofetilide are moderately effective in patients with chronic 
atrial fibrillation. However, amiodarone appears to be most efficacious. Moreover, 
amiodarone and dofetilide is efficacious in patients who have had a myocardial infarction and 
those with heart failure. The safety of commercially available d,l-sotalol in these patients is 
poorly understood. Torsades de pointes is the most serious adverse effect of sotalol and 
dofetilide. Amiodarone has minimal proarrhythmic risk, but has numerous noncardiac 
toxicities that require frequent monitoring. Dronedarone, a noniodinated benzofuran 
derivative, has been shown to be more effective in vivo than amiodarone in several 
arrhythmia models, particularly in preventing ischemia- and reperfusion-induced ventricular 
fibrillation and in reducing mortality. However, further experimental studies and long-term 
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clinical trials are required to provide additional evidence of efficacy and safety of this drug. 
Azimilide statistically reduced the incidence of new atrial fibrillation in recent survivors of 
myocardial infarction at high risk for sudden cardiac death. In addition, class III 
antiarrhythmic agents are increasingly being used as adjunct therapy to decrease the 
frequency of ICD discharges in patients with ventricular arrhythmias and implantable 
cardioverter defibrillators (ICDs). The antiarrhythmic efficacy of most pure class III drugs is 
compromised by their inherent property to induce excessive lengthening of the action 
potential (reverse frequency dependence) and their inability to prolong the action potential 
when most needed, namely during tachycardia. Overall, an ideal antiarrhythmic agent does 
not exist, and drug selection should be highly individualized.  
Based on these results in antiarrhythmic field we synthesized a series of molecules that 
combine several modes of actions to find a drug that has powerful antiarrhythmic potential 
with lack of proarrhythmic side effects. One possible direction of development was to test the 
combination of the hydroxy-benzopyran ring of vitamin E with the methylsulfonyl-
aminophenyl moiety of class III antiarrhythmic drugs. Specifically, the new compounds 
combine pharmacophores identified for the most active Class III antiarrhythmics. Thus, they 
contain two aromatic rings, one methylsulfonyl amino group, and at least one tertiary amine, 
such as a 1,4-piperazine or methylamine moiety.  
Evaluation of the antiarrhythmic and antioxidant activity of the new compounds was 
carried out on isolated rat heart preparations using the non-recirculating Langendorff mode. 
The new analogues were present, at 10 µM concentration, during ischaemia and reperfusion. 
Selected compounds were further studied by a conventional microelectrode method in order 
to get insight into their cellular mode of action.  
Another possible area for development of new antiarrhythmics are amiodarone-like 
drugs, that combine Class IB+III antiarrhythmic effects. Our chemical collaboration partner 
designed and developed a new agent, SZV-123, that based on some preliminary screening 
proved to have strong antiarrhythmic potential, therefore it was selected for a more intensive 
electrophysiological screening project. We have analysed the effects of SZV-123 on the 
action potential parameters and main repolarizing transmembrane ionic currents by applying 
the conventional and whole-cell patch-clamp techniques. 
Ventricular repolarization is governed by a fine balance between inward currents, such 
as the fast sodium (INa) and the L-type calcium (ICa) currents, and outward currents, such as 
the transient outward (Ito), rapid delayed rectifier (IKr), slow delayed rectifier (IKs) and inward 
rectifier (IK1) potassium current. Under normal conditions impairment or block of one type of 
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outward potassium currents can not be expected to cause excessive and potentially dangerous 
APD lengthening, since other potassium currents may provide sufficient repolarizing 
capacity, which can be considered as a “repolarization reserve”. However, in situations where 
the density of one or more types of potassium channels is decreased by inheritance or 
remodelling, inhibition of other potassium channels may lead to unexpectedly augmented 
APD prolongation, resulting in proarrhythmic reactions. Genetic channelophathies of certain 
potassium channels, which normally contribute to repolarization, can attenuate the capability 
of the heart to repolarize.  
The rapid component of the delayed rectifier potassium current (IKr) has been 
identified in several mammalian species, including human. Pharmacological agents that 
selectively block IKr (e.g., E-4031, sotalol and dofetilide) markedly increase APD, QT 
duration and ventricular refractoriness, and high doses of these drugs are associated with the 
induction of Torsades de Pointes. Mutations in ion channel genes, including HERG and 
KCNE2, that suppress IKr result in a specific form of the inherited long QT syndrome, the 
LQT2, which is also associated with rhythm disorders and an increased incidence of sudden 
cardiac death. As such, IKr plays a major role in action potential repolarization in health and in 
specific cases of arrhythmogenesis.  
The role of the slow delayed rectifier potassium current (IKs) in human ventricular 
muscle action potential repolarization, on the other hand, has been often debated. As with IKr, 
IKs has been identified in several mammalian species, including humans and mutations in 
KCNQ1 and KCNE1, the alpha and beta-subunits of the IKs potassium channel, are associated 
with another specific form of the inherited long QT syndrome, LQT1. We previously reported 
that complete pharmacological block of IKs, by either chromanol 293B or L-735,821, has little 
effect on APD in isolated dog and rabbit ventricular muscle over a wide range of physiologic 
pacing frequencies. These findings led us to speculate that IKs normally plays little role in 
ventricular muscle action potential repolarization. However, when APD is abnormally long, 
IKs likely provides an important safety mechanism that when removed increases arrhythmic 
risk. Our previously reported findings have now been confirmed by other investigators and 
supported by computer simulations suggesting that IKs does not play a role in adaptations of 
APD to changes in heart rate. However, the role of IKs in human ventricular muscle remains 
controversial; although, our preliminary characterization of IKr and IKs in isolated human 
ventricular myocytes suggests that these currents behave much the same as they do in isolated 
dog and rabbit ventricular myocytes. The purpose of the present study, therefore, was to 
confirm our initial findings while further elucidating the role of IKs in normal human 
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ventricular muscle action potential repolarization and in preparations where repolarization 
reserve was attenuated and sympathetic activation was increased by exogenous dofetilide and 
adrenaline. 
In addition, we investigated and compared the role and relative contribution of two 
particularly important repolarizing potassium currents IKr and IK1 to the repolarization in 
human, dog and rabbit hearts at the cellular levels. 
 
 
2. Major specific experimental goals 
 
 
a.) To study the effect of SEA0400, a newly developed NCX inhibitor devoid of ICa 
blocking property, on the NCX and ICa currents of dog ventricular myocytes, and also on 
the formation of EAD and DAD in the dog ventricular muscle and Purkinje fibres.  
b.) To investigate the in vitro electrophysiological effects of a series of molecules that 
combine the hydroxy-benzopyran ring of vitamin E with the methylsulfonyl-aminophenyl 
moiety of Class III antiarrhythmic drugs, that can represent novel cardioprotective 
compounds with improved efficacy in the treatment of life-threatening arrhythmias in 
rabbit cardiac preparations. 
c.) To investigate the in vitro electrophysiological effects of SZV-123, a new amiodarone-
like (combined Class IB+III) antiarrhythmic, that can be a novel cardioprotective 
compound with improved efficacy in the treatment of life-threatening arrhythmias, in dog 
and rabbit cardiac preparations. 
d.) To elucidate the role of IKs current in normal human ventricular muscle, and in 
preparations where repolarization reserve was attenuated and sympathetic activation was 
increased by exogenous dofetilide and adrenaline. 
e.) To study and compare the role and relative contribution of  rapid delayed rectifier IKr 
and inward rectifier potassium currents (IK1) in the repolarization of human, dog and 
rabbit ventricular muscle. 
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3. Methods 
 
 
3.1. Species and cardiac preparations 
 
Experiments were carried out in ventricular preparations isolated from dog, rabbit hearts and 
from undiseased human cardiac ventricular preparations. The protocols used on rabbit and 
dog cardiac preparations were conducted in compliance with the Guide for the Care and Use 
of Laboratory Animals (USA NIH publication No 85-23, revised 1985), and were approved 
by the review board of Committee on Animal Research (CAR) of the Albert Szent-Györgyi 
Medical University (54/1999 OEj).  
Human hearts were obtained from organ donors whose hearts were explanted to obtain 
pulmonary and aortic valves for transplant surgery. Before cardiac explantation, organ donor 
patients did not receive medication, except dobutamine, furosemide, and plasma expanders. 
The investigations conform to the principles outlined in the Declaration of Helsinki and all 
experimental protocols were approved by the Albert Szent-Györgyi Medical University 
Ethical Review Board (No. 51-57/1997). Proper consent was obtained for use of each 
individual’s tissue for experimentation. 
 
3.2. Conventional microelectrode technique 
 
Cardiac preparations (trabeculae, papillary muscle and Purkinje fibres) from untreated 
New-Zealand white rabbits  and adult mongrel dogs of either sex and from undiseased human 
ventricles were used. The preparations were immediately rinsed in oxygenated Locke’s 
solution containing (in mM): NaCl 123, KCl 4.7, NaHCO3 20, CaCl2 1.8, MgCl2 1.0 and D-
glucose 10. The pH of this solution was 7.35 ± 0.05 when gassed with 95% O2 and 5% CO2 at 
37 °C. The tip of the papillary/trabeculae muscles obtained from the right ventricle were 
individually mounted in a tissue chamber (volume 50 ml). Each ventricular preparation was 
initially stimulated (HSE (Hugo Sachs Elektronik) stimulator type 215/II, March-Hugstetten, 
Germany) at a basic cycle length (BCL) of 1000 ms (frequency=1 Hz), using 2 ms rectangular 
constant voltage pulses isolated from ground and delivered across bipolar platinum electrodes 
in contact with the preparation. Each preparation was allowed to equilibrate for least 1, while 
they were continuously superfused with Tyrode’s solution. Temperature of the superfusate 
was kept constant at 37 °C. Transmembrane potentials were recorded using conventional 
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microelectrode techniques. Microelectrodes filled with 3M KCl and having tip resistances of 
15-20 Mohm were connected to the input of a high impedance electrometer (HSE 
microelectrode amplifier type 309), which was connected to ground. The first derivative of 
transmembrane potentials was electronically obtained by an HSE differentiator (type 309). 
The voltage outputs from all amplifiers were displayed on a dual beam memory oscilloscope 
(Tektronix 2230 100 MHz digital storage oscilloscope, Beaverton, OR, USA). 
The maximum diastolic potential, action potential amplitude and action potential 
duration (APD) measured at 50 and 90% repolarization (APD50-90) were obtained using a 
software developed in our department (HSE-APES) on an IBM 386 microprocessor based 
personal computer connected to the digital output of the oscilloscope. After control 
measurements the preparations were superfused for 60 min with Tyrode’s solution containing 
the compound under study, and then the electrophysiological measurements were resumed.  
 
3.3. Whole cell patch-clamp measurements  
 
 Isolation of rabbit, dog and human  ventricular myocytes 
Single ventricular myocytes were obtained by enzymatic dissociation. The cells were 
stored at room temperature in HEPES buffered Tyrode solution. containing (mM): NaCl 144, 
NaH2PO4 0.33, KCl 4.0, CaCl2 1.8, MgCl2 0.53, Glucose 5.5, and HEPES 5.0 at pH of 7.4 
(adjusted with NaOH). 
 
Experimental protocols for potassium current measurements  
Membrane currents (potassium and calcium currents) were recorded with Axopatch-
1D and 200B patch-clamp amplifiers (Axon Instruments, Union City, CA, USA.) using the 
whole-cell configuration of the patch-clamp technique. After establishing a high (1-10 Gohm) 
resistance seal by gentle suction, the cell membrane beneath the tip of the electrode was 
disrupted by suction or by application of 1.5 V electrical pulses for 1-5 ms. The series 
resistance was typically 4-8 Mohm before compensation (50-80%, depending on the voltage 
protocols). Experiments where the series resistance was high, or substantially increased 
during measurement, were discarded. Membrane currents were digitized using a 333 kHz 
analogue-to-digital converter (Digidata 1200 and 1322A, Axon Instruments) under software 
control (pClamp 7.0 and 8.0 Axon Instruments). Analyses were performed using Axon 
(pClamp 8.0) software after low-pass filtering at 1 kHz. All patch-clamp data were collected at 
37 ˚C.  
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3.4. Drugs 
 
SEA-0400 was obtained from Orion Pharma (Espoo, Finland) and was dissolved in 
100 % DMSO to make 30 mM stock solution.  
Series of new drugs that combine the hydroxy-benzopyran ring of vitamin E with the 
methylsulfonyl-aminophenyl moiety of class III antiarrhythmic drugs were synthesised and 
tested. Effects of two families of compounds that were active in ischaemia and reperfusion 
studies were further analysed. One class contained the piperazine analogues, while the other 
contained the methylamino analogues. The compounds were dissolved in 100 % DMSO to 
make 10 mM stock solution.       
IKr blockers D-sotalol (Bristol-Myers Squibb Co., Wallingford, CT, USA), E-4031 
(Institute for Drug Research Ltd., Budapest, Hungary) and dofetilide (synthetised by chemical 
partner) were prepared daily from aqueous or DMSO stock. IKs blockers chromanol 293B 
(Aventis Pharma, Frankfurt, Germany), HMR-1556 (Aventis Pharma) and L-735,821 (Merck-
Sharpe & Dohme Co, West Point, PA, USA) were similarly diluted from stock solutions 
containing 100 % DMSO.  
 
3.5. Statistical analysis 
 
 Results were compared using Student’s t-tests for paired and unpaired data. Differences 
were considered significant when P< 0.05. Data are expressed as mean ± standard error of the 
mean (SEM)  
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4. Results and conclusions 
 
 
The main findings and the conclusions of the present thesis are as follows: 
 
1. The effect of SEA-0400, a newly developed NCX inhibitor devoid of ICa blocking property, 
on the formation of EAD and DAD in the dog ventricular muscle and Purkinje fibers was 
investigated. Evidence has been obtained for the NCX inhibitory activity of SEA-0400 and its 
potency to suppress elementary arrhythmogenic phenomena, such as EAD and DAD. 
Considering the pros and contras, further research is needed with both in vitro and in vivo 
methods to elucidate the potential therapeutic targets and, in a wider sense, the possible 
beneficial effect of specific NCX inhibition [I]. 
 
2. We synthesized and studied a series of compounds combining the hydroxy-benzopyran ring 
of vitamin E with the methylsulfonyl-aminophenyl moiety of class III antiarrhythmic drugs. 
These drugs were the piperazine analogues (5a-5e) and methylamino analogues (19a and 
19b). Among piperazine derivatives, compounds 5c and 5e suppressed reperfusion 
tachycardia, while compound 5e reduced premature beats and MDA content, combining 
antiarrhythmic and antioxidant properties. Methylamino derivative 19a exhibited antioxidant 
activity and reduced premature beats, and induce a fast recovery of the heart during 
reperfusion. Compounds 5c, 19a and 19b facilitated the recovery of QRS and QT intervals 
during reperfusion, to the normal values. The cardioprotective compounds 5c-5e and 19a-19b 
do not induce excessive lengthening of the action potential, exhibiting moderate class III 
antiarrhythmic actions [III]. 
 
3. We studied the cellular electrophysiological effects of SZV-123 a new amiodarone-like 
antiarrhythmic compound that combine Class IB+III actions, in isolated dog and rabbit 
cardiac muscle. SZV-123 lengthened repolarization in a frequency independent manner, and 
decreased Vmax only at faster rates than physiological. This property of the SZV-123 can be 
related to the  Class I/B type sodium channel blocking effect. The frequency dependent Class 
I sodium channel blocking of the SZV-123 can be associated with a mexiletine-like fast 
restoration kinetics therefore it can be expected to decrease the conduction velocity only at 
frequencies higher than physiological.  It can be concluded that SZV-123 indeed possesses an 
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amiodarone-like multichannel blocking (Class I/B + III) antiarrhythmic effects, therefore this 
molecule is promising for treatment of ventricular arrhythmias.  
 
4. The role of IKr and IKs were examined in human cardiac preparations from the hearts of 
individuals without heart disease. IKs current in the absence of sympathetic stimulation plays 
no obvious role in altering action potential repolarization and QT duration at normal heart 
rates in human ventricular myocytes isolated. However, when human ventricular muscle 
repolarization reserve is attenuated and sympathetic stimulation is elevated, IKs plays an 
increasingly important role in limiting action potential prolongation. These findings should 
not be misconstrued as meaning that IKs does not play an important role in the normal heart 
where sympathetic stimulation is allways present and fluctuating continuously. We also 
believe, that IKs is vitally important in the normal heart where it prevents excessive action 
potential prolongation in the setting of an elevated sympathetic tone following a single long 
diastolic interval after the compensatory pause that follows a premature ventricular 
depolarization, or during bradycardia or when APD is prolonged by other means (eg, by 
unintentional IKr block, hypothyroidism, or serum hypokalaemia) [II]. 
 
5. The current density of IK1 is considerably less in human than in the dog and rabbit ventricle, 
while IKr density is about the same in the three preparations. Pharmacological inhibition of IK1 
elicits minor changes in the human ventricle, but prolongs ventricular repolarization in the 
dog and rabbit. Inhibition of IKr evokes modest prolongation of repolarization in the dog 
ventricle, but largely or markedly lengthens it in the rabbit and human, respectively, 
suggesting an important role of IK1 as part of the repolarization in both species but IK1 
contributes more to normal repolarization in the dog and rabbit than in humans. In other 
words based on experiments in the dog with drugs potentially blocking IKr/HERG channels 
one can underestimate the expected degree of repolarization lengthening in human. Therefore 
using dog in certain types of safety pharmacology studies predicting the possible QTc 
lengthening side effects of various non cardiac drugs has no particular advantage over other 
animal models like the commonly used rabbit models even if one considers the more 
similarity the behaviours of the individual channels the better correlation of heart rate between 
human and large than small mammals [IV].  
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